Clinical Nurse Specialist Program year 2025 Source: CMS Open Payments, 2026 publication

Joseph Boone

Clinical Nurse Specialist, Psychiatric/Mental Health, Geropsychiatric Show Low, AZ Clinical Nurse Specialist

NPI 1679383061 CMS profile 11832599

1500 S White Mountain Rd, Show Low, AZ 85901

Open in the dashboard

General payments

$980

42 records reported · program year 2025

Research payments

$0

Paid to them · None reported · program year 2025

Ownership & investment interest

$0

None reported

Through program year 2025, Joseph Boone of Show Low, AZ is reported in the CMS Open Payments database as having received $980 across 42 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

1 row
Year Kind Relative to this record's peak year Amount Records
2025 General $980 42

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joseph Boone
  • Arizona median
  • Middle half of Arizona
  • National median

In program year 2025, general payments to Joseph Boone were reported at $980. Among 22,468 Arizona profiles paid that year, the median was $185 and the middle half received between $57 and $677.

Show as a table
Year Joseph Boone Arizona median Middle half National median
2019 $0 $185 $53–$752 $163
2020 $0 $124 $36–$453 $114
2021 $0 $153 $43–$556 $132
2022 $0 $174 $50–$618 $149
2023 $0 $182 $55–$645 $160
2024 $0 $184 $56–$660 $164
2025 $980 $185 $57–$677 $169

Breakdown

Who paid General payments · program year 2025
  1. Teva Pharmaceuticals USA, Inc. $490 19 payments
  2. Neurocrine Biosciences, Inc. $176 9 payments
  3. Janssen Pharmaceuticals, Inc $103 4 payments
  4. Alkermes, Inc. $72 3 payments
  5. Otsuka America Pharmaceutical, Inc. $59 3 payments
  6. Vanda Pharmaceuticals Inc. $36 2 payments
  7. ITI, Inc. $27 1 payment
  8. AstraZeneca Pharmaceuticals LP $17 1 payment

Every payment, record by record

What the payments were for General payments · program year 2025
  1. Food and Beverage $759 40 payments
  2. Education $221 2 payments
Products named General payments · program year 2025
  1. Austedo XR $178 12 payments
  2. INGREZZA $176 9 payments
  3. SPRAVATO $84 3 payments
  4. UZEDY $61 3 payments
  5. LYBALVI Cns $58 2 payments
  6. LYBALVI Cns $58 2 payments
  7. LYBALVI Cns $58 2 payments
  8. LYBALVI Cns $58 2 payments
  9. ABILIFY ASIMTUFII $44 2 payments
  10. ABILIFY MAINTENA $44 2 payments
  11. Other $158 9 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

42 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record